Clinical features and outcomes in kidney transplant recipients with COVID-19 pneumonia: a single center retrospective cohort study
Frontiers in Cellular and Infection Microbiology · 2024
DOI: 10.3389/fcimb.2024.1392491 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2024. Verfasst von Liang Xu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Organ Transplantation, the Second Affiliated Hospital of Hainan Medical University, Haikou, China. Hauptthemen laut MEDLINE: Kidney Transplantation, Antiviral Agents, COVID-19, SARS-CoV-2. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
This retrospective cohort study aimed to assess the clinical features, treatment outcomes, and short-term prognosis in kidney transplant recipients (KTRs) with concurrent coronavirus disease 2019 (COVID-19) pneumonia.
Methods
KTRs with COVID-19 pneumonia who were admitted to our hospital from December 28, 2022, to March 28, 2023 were included in the study. Their clinical symptoms, responses to antiviral medications, and short-term prognosis were analyzed.
Results
A total of 64 KTRs with initial diagnosis of COVID-19 pneumonia were included in this study. The primary symptoms were fever, cough, and myalgia, with an incidence of 79.7%, 89.1%, and 46.9%, respectively. The administration of antiviral drugs (paxlovid or molnupiravir) within 1–5 days and for over 5 days demonstrated a statistically significant reduction in viral shedding time compared to the group without antiviral medication (P=0.002). Both the paxlovid and molnupiravir treatment groups exhibited a significantly shorter duration of viral shedding time in comparison to the group without antiviral drugs (P=0.002). After 6 months of recovery, there was no significantly negative impact on transplant kidney function (P=0.294).
Conclusion
Fever, cough, and myalgia remain common initial symptoms of concurrent COVID-19 pneumonia in KTRs. Early use of antiviral drugs (paxlovid or molnupiravir) is associated with better therapeutic outcomes. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had a limited impact on the short-term renal function of the KTRs with concurrent moderate or severe COVID-19 pneumonia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Organ Transplantation, the Second Affiliated Hospital of Hainan Medical University, Haikou, China.
- Department of Breast and Thyroid Surgery, the Second Affiliated Hospital of Hainan Medical University, Haikou, China.
- Department of Scientific Affaires, Hugobiotech Co., Ltd., Beijing, China.
- Department of Nephrology, Hainan Affiliated Hospital of Hainan Medical University, Haikou, China.
- Organ Transplant Center, Tianjin First Central Hospital, Tianjin, China.
Zitieren
APA
Xu, L., Chen, X., Yang, X., Chen, S., Yang, M., Yuan, Z., Chen, R., Wang, J., Jiang, H., Xu, J., & Wang, Y. (2024). Clinical features and outcomes in kidney transplant recipients with COVID-19 pneumonia: a single center retrospective cohort study. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2024.1392491
Vancouver
Xu L, Chen X, Yang X, Chen S, Yang M, Yuan Z, et al. Clinical features and outcomes in kidney transplant recipients with COVID-19 pneumonia: a single center retrospective cohort study. Frontiers in Cellular and Infection Microbiology. 2024. doi:10.3389/fcimb.2024.1392491
BibTeX
@article{Xu2024,
author = {Xu, Liang and Chen, Xiuxiu and Yang, Xuying and Chen, Song and Yang, Meng and Yuan, Zehua and Chen, Rentian and Wang, Jianli and Jiang, Hongtao and Xu, Jian and Wang, Yi},
title = {Clinical features and outcomes in kidney transplant recipients with COVID-19 pneumonia: a single center retrospective cohort study},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2024},
doi = {10.3389/fcimb.2024.1392491}
}
EUVIMED